Exobiosphere
Latest round
- Seed
Last raised
- May 2025
Total raised
- $2.2M
Investors
- 4
About Exobiosphere
Exobiosphere develops biopharmaceutical solutions, utilizing unique space-based technologies for drug discovery, particularly in microgravity environments, targeting advancements in disease modeling and therapeutic development. Exobiosphere is focused on creating advanced biopharmaceutical solutions through its innovative Orbital High-Throughput System. Founded in 2024 by Kyle Acierno (CEO), Bruno Santos, and Olivia Borgue, the company is headquartered in Esch-sur-Alzette, Luxembourg., Expon Capital, and SpaceData Inc. Exobiosphere specializes in advanced biopharmaceutical solutions through its core offering, the Orbital High-Throughput System. This technology supports large-scale, automated testing in space, enabling the development of microgravity-based disease models. By utilizing microgravity, the company enhances drug discovery processes, allowing researchers to identify novel molecular targets and characterize disease traits with improved accuracy. Exobiosphere serves a diverse clientele, including pharmaceutical companies and research institutions, particularly in North America, Europe, and Asia. Exobiosphere's revenue model is centered around partnerships with pharmaceutical companies and research institutions, primarily through B2B transactions. The company generates income via contracts for research services, which may involve subscriptions for access to its high-throughput screening capabilities. Their focus on oncology, neuro-degeneration, and other therapeutic areas allows for tailored offerings to meet client needs, with pricing defined by project scope and service level requirements. The company is expected to develop new products aimed at enhancing its biopharmaceutical capabilities and exploring additional markets, particularly targeting North America and Asia by the end of 2026.
Who invested in Exobiosphere
4 investors across 1 round
See all investors in Exobiosphere
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Seed
May 23, 2025
Amount
$2.2M
Investors
Questions about Exobiosphere
Who invested in Exobiosphere?
Exobiosphere has 4 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Exobiosphere raised?
Exobiosphere has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Exobiosphere last raise money?
Exobiosphere's most recent round on record is a Seed, in May 2025.
What does Exobiosphere do?
Exobiosphere develops biopharmaceutical solutions, utilizing unique space-based technologies for drug discovery, particularly in microgravity environments, targeting advancements in disease modeling and therapeutic development.
Where is Exobiosphere headquartered?
Exobiosphere is headquartered in Esch-sur-Alzette, Luxembourg.
Which VCs invest in companies like Exobiosphere?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Balderton Capital back biotechnology companies at Exobiosphere's stage. Their profiles are linked below.
VCs backing biotechnology startups at Seed
Raising like Exobiosphere? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.